Vaccinex Announces Three Oral Presentations Highlighting Semaphorin 4D (SEMA4D) at the ASCO-SITC Clinical Immuno-Oncology Symposium

Author's Avatar
Feb 06, 2020
Article's Main Image

The multiple presentations in one ASCO-SITC meeting session spotlight the growing interest in SEMA4D as a clinically relevant target implicated in multiple cancer types and highlights the potential of pepinemab antibody to neutralize SEMA4D in the treatment of cancer